2023-12-15 15:00:00
Vertex signs licensing agreement with Editas Medicine
Vertex has just signed a licensing agreement with the American biotech Editas Medicine for its Cas9 gene editing technology, CRISPR scissors. This agreement includes Casgevy (exagamglogene autotemcel), a cell therapy from Vertex approved in early December by the FDA once morest sickle cell disease. Thanks to this agreement, which according to several media might reach $100 million (€91 million), Editas Medicine’s cash flow is extended until 2026.
Sandoz begins its Slovenian project
The laboratory specializing in generic and biosimilar medicines, now independent, announced that it has started the construction of its new factory in Lendava, Slovenia. The result of an investment of 400 million euros, the installation will include three buildings, dedicated to the manufacture of organic products. Their cumulative surface area will reach 40,000 m2, with commissioning scheduled for the end of 2026.
VOS INDICES
source
Naobios receives €1.7 million
The Nantes CDMO specializing in vaccines received financial aid of 1.87 million dollars (1.7 million euros) from the Bill & Melinda Gates Foundation. Thanks to this amount, Naobios wants to develop and produce an HVCA (Human viral challenge agent) of the Omicron variant of SARS-CoV-2, to accelerate the development of vaccines. The vaccine in question is intended to be administered into the mucous membranes and will be intended for low- and middle-income countries.
Pfizer completes Seagen transaction
After the green light from the Federal Trade Commission (FTC), Pfizer has finalized the $43 billion purchase of the American biotech company Seagan. The operation was definitively concluded on December 14, following being announced last March. Seagen develops and commercializes compounds positioned in oncology, particularly antibody-drug conjugates (ADCs). For 2024, Pfizer expects biotech products to generate $3.1 billion in sales.
Selected for you
1702708570
#bref #Vertex #Sandoz #Naobios #Pfizer